Search

Your search keyword '"Van Rhijn B"' showing total 62 results

Search Constraints

Start Over You searched for: Author "Van Rhijn B" Remove constraint Author: "Van Rhijn B" Database Unpaywall Remove constraint Database: Unpaywall
62 results on '"Van Rhijn B"'

Search Results

1. Urologische oncologie

2. Stage dependent survival in patients treated with NAC and RC: Implications for patient selection and adjuvant therapy

3. Factores de riesgo de enfermedad residual en la re-RTU en una gran cohorte de pacientes con enfermedad T1G3

4. Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients

5. OC-0103 Comparative study of brachytherapy vs. radical cystectomy for cT1-2 muscle-invasive bladder cancer

7. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer patients without hydronephrosis: results from a large multicenter cohort study

10. Prediction of early (30-day) and late (30–90-day) mortality after radical cystectomy in a comprehensive cancer centre over two decades

11. L’impact de l’intoxication tabagique sur la réponse à la chimiothérapie néoadjuvante à base de sels de platine chez les patients traités pour carcinome urothélial de vessie – étude prospective multicentrique

12. Carcinome urothélial au sein d’un diverticule de vessie : étude multicentrique des caractéristiques cliniques, anatomopathologiques et des résultats oncologiques

13. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

14. Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy

15. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought

16. Urothelial carcinoma in bladder diverticula: A multicenter analysis of characteristics and treatment outcome in 110 patients

17. Cigarette smoking is adversely associated with pathological response to platinum-based neoadjuvant chemotherapy in patients undergoing treatment for urinary bladder cancer

18. Value of repeated ureterorenoscopy within the first 3 months after endoscopic treatment in upper tract urothelial carcinoma (UTUC)

19. Biological characterization of cisplatin-resistant bladder cancer: Implications for second-line treatments?

20. Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer

21. The impact of cigarette smoking on adverse pathological features and survival in patients undergoing radical cystectomy for urinary bladder cancer - a prospective, European multicenter study of the EAU young academic urologists urothelial carcinoma group

22. Disease and patient’s characteristics in elderly (≥75 years) treated with radical cystectomy: results of a large multicentre retrospective series

25. Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer

28. Metric sub-stage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer

31. Recurrence and progression according to stage at re-TUR in t1g3 bladder cancer patients treated with BCG: Not as bad as previously thought

35. 508 The impact of cigarette smoking and smoking cessation on oncological aggressiveness at radical cystectomy – a prospective, European, multicenter study of the EAU Young Academic Urologists (YAU) bladder cancer working group

36. 1016 Are continent urinary diversions feasible at the time of radical cystectomy after pelvic radiotherapy? Analysis of a large retrospective multicenter series

37. 620 Complication rates after radical cystectomy following any previous abdominal-pelvic-perineal radiotherapy: An international, multicenter retrospective study on 609 cases

41. 532 Final pathologic stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer: Does pT0 predict better survival than pTa/pTis/pT1?

42. Le Fibroblast Growth Factor Receptor 3 (FGFR3), cible thérapeutique pour le traitement personnalisé du cancer de la vessie : validation anatomo-pathologique du concept

43. 900 Sub-stage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer

44. 1001 The impact of re-TUR on clinical outcomes in a large cohort of t1g3 patients treated with BCG

45. 412 Pathological validation of adjuvant anti-fibroblast growth factor receptor 3 (FGFR3) treatment for bladder cancer

49. 697 Prognostic factors and risk groups in T1G3 patients initially treated with BCG: Results of a multicenter retrospective series in 1743 patients

Catalog

Books, media, physical & digital resources